
Editas Medicine Restructures, Cuts Workforce Amid Strategic Shift
Editas Medicine has announced a strategic shift to focus on in vivo gene editing, aiming for human proof of concept by 2026. This realignment includes significant workforce reductions, cutting 65% of its staff, to streamline operations and extend its cash runway into 2027. Recent preclinical advancements in gene editing, particularly in hematopoietic stem cells and liver applications, have prompted this transition. The company plans to share more detailed data and timelines in 2025, while its stock saw a decline following the announcement.







